FGF19

Across TCGA pan-cancer cohorts, FGF19 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of FGF19’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FGF19 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FGF19 is over-expressed in tumor, although a few such as BRCA and CHOL show the opposite, repressed pattern.

HNSC, COAD, and UCEC are the cancer types where FGF19 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FGF19 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	+0.756	<.001	9	view →
COAD	All	II,III,IV	+1.081	<.001	8	view →
UCEC	All	All	+1.759	<.001	6	view →
BRCA	Female	II,III,IV	−0.162	<.001	6	view →
LUSC	All	All	+1.010	.001	4	view →
STAD	All	All	+0.565	.004	4	view →
LUAD	All	All	+0.435	<.001	4	view →
THCA	All	All	+0.093	.006	4	view →
LIHC	All	All	+0.566	.036	3	view →
READ	All	All	+2.551	.007	2	view →
CHOL	Female	All	−0.099	.013	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

FGF19–HNSC

Open the HNSC breakdown →